Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II haploidentical bone marrow transplantation with reduced-intensity conditioning and post-transplant cyclophosphamide in poor-prognosis lymphomas
2012-005580-27Phase 2Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in lymphoma, sponsored by Humanitas Research Hospital. Primary endpoint: 1-year progression-free survival. Started Feb 2013; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
lymphoma
Beyond the preview
Go deeper on 2012-005580-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005580-27.